COX-2 inhibitors and cardiovascular risk.

Progress in cardiovascular nursing

Volumn 20, Issue 3, 2005, Pages 123-125

  Flattery, Maureen P ^a   Hylton Gravatt, Leigh Anne ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; TIME; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; MEMBRANE PROTEINS; PATIENT SELECTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAFETY; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 24944476694     PISSN: 08897204     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0889-7204.2005.04034.x     Document Type: Review

References (17)